2100 Manufacture of pharmaceuticals, medicinal chemical and botanical products

Code: 
2100

Most active institutional investors by number of deals

Investor Profile Country Deals
GeneChem Management Inc Venture capital firm targeting companies in the genomics industry Canada 5
Genentech Inc Discovery, development, commercialization and manufacturing of biotherapeutics by using human genetic information United States 5
Glynn Capital Management LLC United States 5
Granite Global Ventures LLC Venture capital firm United States 5
Hamilton BioVentures United States 5
Hatteras Venture Partners II United States 5
Infinity USA United States 5
Integra Ventures United States 5
Lehman Brothers Holdings Inc United States 5
LLR Equity Partners LP United States 5
MDV - Mohr Davidow Ventures United States 5
Mediphase Venture Partners United States 5
MedVenture Associates Venture capital firm focused on seed and early stage investments in the field of medical technology (medical devices, instrumentation and diagnostics) United States 5
Merlin Nexus United States 5
Oxford Bioscience Partners III LP United States 5
Pacific Horizon Ventures LLC United States 5
Palo Alto Investors Independent, privately held investment advisor located in Palo Alto, California 5
Pinnacle Ventures United States 5
Prism VentureWorks United States 5
PureTech Ventures LLC United States 5

Pages

Selected funding rounds

Date Company Profile Round
Aug 2010 TetraLogic Pharmaceuticals A leader in the discovery and development of small molecule drugs called Smac mimetics for the treatment of cancers. Series C
Aug 2010 TetraLogic Pharmaceuticals A leader in the discovery and development of small molecule drugs called Smac mimetics for the treatment of cancers. Series C
Aug 2010 TetraLogic Pharmaceuticals A leader in the discovery and development of small molecule drugs called Smac mimetics for the treatment of cancers. Series C
Aug 2010 TetraLogic Pharmaceuticals A leader in the discovery and development of small molecule drugs called Smac mimetics for the treatment of cancers. Series C
Aug 2010 TetraLogic Pharmaceuticals A leader in the discovery and development of small molecule drugs called Smac mimetics for the treatment of cancers. Series C
Jul 2010 Zogenix Inc A pharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. Debt
Jul 2010 Liquidia Technologies Inc Series C
Jul 2010 Calithera Biosciences Inc Series A
Jul 2010 Liquidia Technologies Inc Series C
Jul 2010 Zogenix Inc A pharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. N/A
Jul 2010 Liquidia Technologies Inc Series C
Jul 2010 Cerenis Therapeutics SA Series C
30 Jun 2010 Calistoga Pharmaceuticals Inc Biopharmaceutical company dedicated to developing targeted therapies to improve the health of patients with cancer or inflammatory diseases. Series C
Jun 2010 Tetraphase Pharmaceuticals Inc A biopharmaceutical company utilizing a synthetic chemistry technology platform to treat drug-resistant bacterial infections. Series C
Jun 2010 Constellation Pharmaceuticals Inc Rapidly Advancing Emerging Epigenetics Research to Develop Novel Oncology Therapeutics Series B
Jun 2010 Tetraphase Pharmaceuticals Inc A biopharmaceutical company utilizing a synthetic chemistry technology platform to treat drug-resistant bacterial infections. Series C
Jun 2010 Constellation Pharmaceuticals Inc Rapidly Advancing Emerging Epigenetics Research to Develop Novel Oncology Therapeutics Series B
Jun 2010 Tetraphase Pharmaceuticals Inc A biopharmaceutical company utilizing a synthetic chemistry technology platform to treat drug-resistant bacterial infections. Series C
Jun 2010 Constellation Pharmaceuticals Inc Rapidly Advancing Emerging Epigenetics Research to Develop Novel Oncology Therapeutics Series B
Jun 2010 Tetraphase Pharmaceuticals Inc A biopharmaceutical company utilizing a synthetic chemistry technology platform to treat drug-resistant bacterial infections. Series C

Pages

Selected companies

Company type: 
A privately-owned pharmaceutical company optimizing therapies for disorders of the Central Nervous System to improve sufferers’ lives.
Company type: 
Personalized medicine company specializing in pharmacogenetics
Company type: 
Switzerland-based drug company focused on CNS disorders
Subscribe to RSS - 2100 Manufacture of pharmaceuticals, medicinal chemical and botanical products